Gene expression profiling and DNA methylation analyses of CTCs

Molecular Oncology

Volumn 10, Issue 3, 2016, Pages 431-442

  Lianidou, Evi S ^a  

^a UNIVERSITY OF ATHENS   (Greece)

Author keywords

Circulating Tumor Cells; CTCs; Gene expression; Methylation specific PCR; Molecular assays; Molecular characterization; Multiplex RT PCR; Quantitative PCR (qPCR); Reverse transcription PCR; RT qPCR

Indexed keywords

ANDROGEN RECEPTOR; AR V7 PROTEIN; BREAST CANCER METASTASIS SUPPRESSOR 1; CST6 PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN; TRANSCRIPTION FACTOR SOX17; UNCLASSIFIED DRUG;

BREAST CANCER; BREAST METASTASIS; CIRCULATING TUMOR CELL; COLORECTAL CANCER; DNA METHYLATION; GENE EXPRESSION PROFILING; HUMAN; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; ANIMAL; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; NEOPLASM; PATHOLOGY; POLYMERASE CHAIN REACTION; PROCEDURES; TUMOR EMBOLISM;

ANIMALS; DNA METHYLATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASMS; NEOPLASTIC CELLS, CIRCULATING; POLYMERASE CHAIN REACTION;

EID: 84959116079     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2016.01.011     Document Type: Review

References (107)

1. Ai L., Kim W., Kim T.Y., et al. Epigenetic silencing of the tumor suppressor cystatin M occurs during breast cancer progression. Cancer Res. 2006, 66:7899-7909.
2. Aktas B., Müller V., Tewes M., et al. Comparison of estrogen and progesterone receptor status of circulating tumor cells and the primary tumor in metastatic breast cancer patients. Gynecol. Oncol. 2011, 122:356-360.
3. Aktas B., Kasimir-Bauer S., Heubner M., et al. Molecular profiling and prognostic relevance of circulating tumor cells in the blood of ovarian cancer patients at primary diagnosis and after platinum-based chemotherapy. Int. J. Gynecol. Cancer 2011, 21:822-830.
4. Alix-Panabières C., Pantel K. Circulating tumor cells: liquid biopsy of cancer. Clin. Chem. 2013, 59:110-118.
5. Andergassen U., Kölbl A.C., Hutter S., et al. Detection of circulating tumour cells from blood of breast cancer patients via RT-qPCR. Cancers (Basel) 2013, 5:1212-1220.
6. Androulakis N., Agelaki S., Perraki M., et al. Clinical relevance of circulating CK-19mRNA-positive tumour cells before front-line treatment in patients with metastatic breast cancer. Br. J. Cancer 2012, 106:1917-1925.
7. Antonarakis E.S., Lu C., Wang H., Luber B., Nakazawa M., Roeser J.C., Chen Y., Mohammad T.A., Chen Y., Fedor H.L., Lotan T.L., Zheng Q., De Marzo A.M., Isaacs J.T., Isaacs W.B., Nadal R., Paller C.J., Denmeade S.R., Carducci M.A., Eisenberger M.A., Luo J. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N. Engl. J. Med. 2014 Sep 11, 371(11):1028-1038.
8. Antonarakis E.S., Lu C., Luber B., Wang H., Chen Y., Nakazawa M., Nadal R., Paller C.J., Denmeade S.R., Carducci M.A., Eisenberger M.A., Luo J. Androgen receptor splice variant 7 and efficacy of taxane chemotherapy in patients with metastatic castration-resistant prostate cancer. JAMA Oncol. 2015 Aug, 1(5):582-591.
9. Attard G., Swennenhuis J.F., Olmos D., et al. Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer. Cancer Res. 2009, 69:2912-2918.
10. Balgkouranidou I., Chimonidou M., Milaki G., Tsarouxa E.G., Kakolyris S., Welch D.R., Georgoulias V., Lianidou E.S. Breast cancer metastasis suppressor-1 promoter methylation in cell-free DNA provides prognostic information in non-small cell lung cancer. Br. J. Cancer 2014 Apr 15, 110(8):2054-2062.
11. Bao H., Burke P.A., Huang J., et al. Circulating tumor cells: application as a biomarker for molecular characterization and predictor of survival in an all-comer solid tumor phase I clinical study. PLoS One 2013, 8:e58557.
12. Becker T.M., Caixeiro N.J., Lim S.H., et al. New frontiers in circulating tumor cell analysis - a reference guide for biomolecular profiling towards translational clinical use. Int. J. Cancer 2014, 134(11):2523-2533.
13. Bednarz-Knoll N., Alix-Panabières C., Pantel K. Plasticity of disseminating cancer cells in patients with epithelial malignancies. Cancer Metastasis Rev. 2012, 31:673-687.
14. Bernard P., Wittwer C.T. Real time PCR technology for cancer diagnostics. Clin. Chem. 2002, 48:1178-1185.
15. Bidard F.C., Fehm T., Ignatiadis M., et al. Clinical application of circulating tumor cells in breast cancer: overview of the current interventional trials. Cancer Metastasis Rev. 2012, 32:179-188.
16. Chen Y., Zou T.N., Wu Z.P., et al. Detection of cytokeratin 19, human mammaglobin, and carcinoembryonic antigen-positive circulating tumor cells by three-marker reverse transcription-PCR assay and its relation to clinical outcome in early breast cancer. Int. J. Biol. Markers 2010, 25:59-68.
17. Chimonidou M., Strati A., Tzitzira A., et al. DNA methylation of tumor suppressor and metastasis suppressor genes in circulating tumor cells. Clin. Chem. 2011, 57:1169-1177.
18. Chimonidou M., Strati A., Malamos N., et al. SOX17 promoter methylation in circulating tumor cells and matched cell-free DNA isolated from plasma of patients with breast cancer. Clin. Chem. 2013, 59:270-279.
19. Chimonidou M., Kallergi G., Georgoulias V., et al. Breast cancer metastasis suppressor-1 promoter methylation in primary breast tumors and corresponding circulating tumor cells. Mol. Cancer Res. 2013, 10:1248-1257.
20. Chimonidou M., Tzitzira A., Strati A., Sotiropoulou G., Sfikas C., Malamos N., Georgoulias V., Lianidou E. CST6 promoter methylation in circulating cell-free DNA of breast cancer patients. Clin. Biochem. 2013 Feb, 46(3):235-240.
21. Chong M.H., Zhao Y., Wang J., et al. The dynamic change of circulating tumour cells in patients with operable breast cancer before and after chemotherapy based on a multimarker QPCR platform. Br. J. Cancer 2012, 106:1605-1610.
22. Coumans F., Terstappen L. Detection and characterization of circulating tumor cells by the CellSearch approach. Methods Mol. Biol. 2015, 1347:263-278.
23. Cristofanilli M., Budd G.T., Ellis M.J., et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N. Engl. J. Med. 2004, 351:781-791.
24. Danila D.C., Fleisher M., Scher H.I. Circulating tumor cells as biomarkers in prostate cancer. Clin. Cancer Res. 2011, 17:3903-3912.
25. Danila D.C., Anand A., Sung C.C., et al. TMPRSS2-ERG status in circulating tumor cells as a predictive biomarker of sensitivity in castration-resistant prostate cancer patients treated with abiraterone acetate. Eur. Urol. 2011, 60:897-904.
26. Daskalaki A., Agelaki S., Perraki M., et al. Detection of cytokeratin-19 mRNA-positive cells in the peripheral blood and bone marrow of patients with operable breast cancer. Br. J. Cancer 2009, 101:589-597.
27. de Albuquerque A., Kubisch I., Stölzel U., et al. Prognostic and predictive value of circulating tumor cell analysis in colorectal cancer patients. J. Transl Med. 2012, 10:222.
28. de Albuquerque A., Kubisch I., Breier G., et al. Multimarker gene analysis of circulating tumor cells in pancreatic cancer patients: a feasibility study. Oncology 2012, 82:3-10.
29. de Wit S., van Dalum G., Lenferink A.T., Tibbe A.G., Hiltermann T.J., Groen H.J., van Rijn C.J., Terstappen L.W. The detection of EpCAM(+) and EpCAM(-) circulating tumor cells. Sci. Rep. 2015 Jul 17, 5:12270.
30. Fehm T., Hoffmann O., Aktas B., et al. Detection and characterization of circulating tumor cells in blood of primary breast cancer patients by RT-PCR and comparison to status of bone marrow disseminated cells. Breast Cancer Res. 2009, 11:R59.
31. Fehm T., Müller V., Aktas B., et al. HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial. Breast Cancer Res. Treat 2010, 124:403-412.
32. Fina E., Callari M., Reduzzi C., D'Aiuto F., Mariani G., Generali D., Pierotti MA,Daidone M.G., Cappelletti V. Gene expression profiling of circulating tumor cells in breast cancer. Clin. Chem. 2015 Jan, 61(1):278-289.
33. Friedlander T.W., Ngo V.T., Dong H., Premasekharan G., Weinberg V., Doty S., Zhao Q., Gilbert E.G., Ryan C.J., Chen W.T., Paris P.L. Detection and characterization of invasive circulating tumor cells derived from men with metastatic castration-resistant prostate cancer. Int. J. Cancer 2014 May 15, 134(10):2284-2293.
34. Georgoulias V., Bozionelou V., Agelaki S., et al. Trastuzumab decreases the incidence of clinical relapses in patients with early breast cancer presenting chemotherapy-resistant CK-19mRNA-positive circulating tumor cells: results of a randomized phase II study. Ann. Oncol. 2012, 23:1744-1750.
35. Heitzer E., Auer M., Gasch C., Pichler M., Ulz P., Hoffmann E.M., Lax S., Waldispuehl-Geigl J., Mauermann O., Lackner C., Höfler G., Eisner F., Sill H., Samonigg H., Pantel K., Riethdorf S., Bauernhofer T., Geigl J.B., Speicher M.R. Complex tumor genomes inferred from single circulating tumor cells by array-CGH and next-generation sequencing. Cancer Res. 2013 May 15, 73(10):2965-2975.
36. Hurst D.R., Edmonds M.D., Scott G.K., Benz C.C., Vaidya K.S., Welch D.R. Breast cancer metastasis suppressor 1 up-regulates miR-146, which suppresses breast cancer metastasis. Cancer Res. 2009, 69:1279-1283.
37. Ignatiadis M., Xenidis N., Perraki M., et al. Different prognostic value of cytokeratin-19 mRNA positive circulating tumor cells according to estrogen receptor and HER2 status in early-stage breast cancer. J. Clin. Oncol. 2007, 25:5194-5202.
38. Ignatiadis M., Kallergi G., Ntoulia M., et al. Prognostic value of the molecular detection of circulating tumor cells using a multimarker reverse transcription-PCR assay for cytokeratin 19, mammaglobin A, and HER2 in early breast cancer. Clin. Cancer Res. 2008, 14:2593-2600.
39. Ignatiadis M., Rothé F., Chaboteaux C., et al. HER2-positive circulating tumor cells in breast cancer. PLoS One 2011, 6:e15624.
40. Ignatiadis M., Riethdorf S., Bidard F.C., Vaucher I., Khazour M., Rothé F., Metallo J., Rouas G., Payne R.E., Coombes R., Teufel I., Andergassen U., Apostolaki S., Politaki E., Mavroudis D., Bessi S., Pestrin M., Di Leo A., Campion M., Reinholz M., Perez E., Piccart M., Borgen E., Naume B., Jimenez J., Aura C., Zorzino L., Cassatella M., Sandri M., Mostert B., Sleijfer S., Kraan J., Janni W., Fehm T., Rack B., Terstappen L., Repollet M., Pierga J.Y., Miller C., Sotiriou C., Michiels S., Pantel K. International study on inter-reader variability for circulating tumor cells in breast cancer. Breast Cancer Res. 2014 Apr 23, 16(2):R43.
41. Ignatiadis M., Lee M., Jeffrey S.S. Circulating tumor cells and circulating tumor DNA: challenges and opportunities on the path to clinical utility. Clin. Cancer Res. 2015 Nov 1, 21(21):4786-4800.
42. Iinuma H., Watanabe T., Mimori K., et al. Clinical significance of circulating tumor cells, including cancer stem-like cells, in peripheral blood for recurrence and prognosis in patients with Dukes' stage B and C colorectal cancer. J. Clin. Oncol. 2011, 29. 1547-1455.
43. Kasimir-Bauer S., Hoffmann O., Wallwiener D., et al. Expression of stem cell and epithelial-mesenchymal transition markers in primary breast cancer patients with circulating tumor cells. Breast Cancer Res. 2012, 14:R15.
44. Kioulafa M., Balkouranidou I., Sotiropoulou G., Kaklamanis L., Mavroudis D., Georgoulias V., Lianidou E.S. Methylation of cystatin M promoter is associated with unfavorable prognosis in operable breast cancer. Int. J. Cancer 2009 Dec 15, 125(12):2887-2892.
45. Korkaya H., Wicha M.S. HER2 and breast cancer stem cells: more than meets the eye. Cancer Res. 2013, 73:3489-3493.
46. Kuhlmann J.D., Wimberger P., Bankfalvi A., Keller T., Schöler S., Aktas B., Buderath P., Hauch S., Otterbach F., Kimmig R., Kasimir-Bauer S. ERCC1-positive circulating tumor cells in the blood of ovarian cancer patients as a predictive biomarker for platinum resistance. Clin. Chem. 2014 Oct, 60(10):1282-1289.
47. Le A.V., Huang D., Blick T., Thompson E.W., Dobrovic A. An optimised direct lysis method for gene expression studies on low cell numbers. Sci. Rep. 2015 Aug 5, 5:12859. PubMed PMID: 26242641; PubMed Central PMCID: PMC4525356. 10.1038/srep12859.
48. Li Y., Lv Z., He G., Wang J., Zhang X., Lu G., Ren X., Wang F., Zhu X., Ding Y., Liao W., Ding Y., Liang L. The SOX17/miR-371-5p/SOX2 axis inhibits EMT, stem cell properties and metastasis in colorectal cancer. Oncotarget 2015 Apr 20, 6(11):9099-9112.
49. Lianidou E.S., Markou A. Circulating tumor cells in breast cancer: detection systems, molecular characterization, and future challenges. Clin. Chem. 2011, 57:1242-1255.
50. Lianidou E.S., Markou A., Strati A. Molecular characterization of circulating tumor cells in breast cancer: challenges and promises for individualized cancer treatment. Cancer Metastasis Rev. 2012, 31:663-671.
51. Lianidou E.S., Mavroudis D., Georgoulias V. Clinical challenges in the molecular characterization of circulating tumour cells in breast cancer. Br. J. Cancer 2013, 108:2426-2432.
52. Lim J., Thiery J.P. Epithelial-mesenchymal transitions: insights from development. Development 2012, 139:3471-3486.
53. Markou A., Strati A., Malamos N., et al. Molecular characterization of circulating tumor cells in breast cancer by a liquid bead array hybridization assay. Clin. Chem. 2011, 57:421-430.
54. Maughan B.L., Antonarakis E.S. Clinical relevance of androgen receptor splice variants in castration-resistant prostate cancer. Curr. Treat Options Oncol. 2015 Dec, 16(12):57.
55. Metge B.J., Frost A.R., King J.A., et al. Epigenetic silencing contributes to the loss of BRMS1 expression in breast cancer. Clin. Exp. Metastasis 2008, 25:753-763.
56. Miyamoto D.T., Zheng Y., Wittner B.S., Lee R.J., Zhu H., Broderick K.T., Desai R., Fox D.B., Brannigan B.W., Trautwein J., Arora K.S., Desai N., Dahl D.M., Sequist L.V., Smith M.R., Kapur R., Wu C.L., Shioda T., Ramaswamy S., Ting D.T., Toner M., Maheswaran S., Haber D.A. RNA-Seq of single prostate CTCs implicates noncanonical Wnt signaling in antiandrogen resistance. Science 2015 Sep 18, 349(6254):1351-1356.
57. Mohamed M.M., Sloane B.F. Cysteine cathepsins: multifunctional enzymes in cancer. Nat. Rev. Cancer 2006, 6:764-775.
58. Mostert B., Sieuwerts A.M., Bolt-de Vries J., Kraan J., Lalmahomed Z., van Galen A., van der Spoel P., de Weerd V., Ramírez-Moreno R., Smid M., Verhoef C., IJzermans J.N., Gratama J.W., Sleijfer S., Foekens J.A., Martens J.W. mRNA expression profiles in circulating tumor cells of metastatic colorectal cancer patients. Mol. Oncol. 2015 Apr, 9(4):920-932.
59. Mostert B., Sieuwerts A.M., Kraan J., Bolt-de Vries J., van der Spoel P., van Galen A., Peeters D.J., Dirix L.Y., Seynaeve C.M., Jager A., de Jongh F.E., Hamberg P., Stouthard J.M., Kehrer D.F., Look M.P., Smid M., Gratama J.W., Foekens J.A., Martens J.W., Sleijfer S. Gene expression profiles in circulating tumor cells to predict prognosis in metastatic breast cancer patients. Ann. Oncol. 2015 Mar, 26(3):510-516.
60. Obermayr E., Sanchez-Cabo F., Tea M.K., et al. Assessment of a six gene panel for the molecular detection of circulating tumor cells in the blood of female cancer patients. BMC Cancer 2010, 10:666.
61. Obermayr E., Castillo-Tong D.C., Pils D., et al. Molecular characterization of circulating tumor cells in patients with ovarian cancer improves their prognostic significance - a study of the OVCAD consortium. Gynecol. Oncol. 2013, 128:15-21.
62. Onstenk W., Sieuwerts A.M., Kraan J., Van M., Nieuweboer A.J., Mathijssen R.H., Hamberg P., Meulenbeld H.J., De Laere B., Dirix L.Y., van Soest R.J., Lolkema M.P., Martens J.W., van Weerden W.M., Jenster G.W., Foekens J.A., de Wit R., Sleijfer S. Efficacy of cabazitaxel in castration-resistant prostate cancer is independent of the presence of AR-V7 in circulating tumor cells. Eur. Urol. 2015 Dec, 68(6):939-945.
63. Pantel K., Alix-Panabieres C. Detection methods of circulating tumor cells. J. Thorac. Dis. 2012, 4:446-447.
64. Pantel K., Alix-Panabieres C., Riethdorf S. Cancer micrometastases. Nat. Rev. Clin. Oncol. 2009, 6:339-351.
65. Parisi C., Markou A., Lianidou E.S. Development of a multiplexed PCR-coupled liquid bead array assay for vascular endothelial growth factor (VEGF) splice variants. Clin. Biochem. 2012 Apr, 45(6):475-482.
66. Parkinson D.R., Dracopoli N., Petty B.G., et al. Considerations in the development of circulating tumor cell technology for clinical use. J. Transl Med. 2012, 10:138.
67. Phadke P.A., Vaidya K.S., Nash K.T., Hurst D.R., Welch D.R. BRMS1 suppresses breast cancer experimental metastasis to multiple organs by inhibiting several steps of the metastatic process. Am. J. Pathol. 2008 Mar, 172(3):809-817.
68. Picelli S., Faridani O.R., Bjorklund A.K., Winberg G., Sagasser S., Sandberg R. Full-length RNA-seq from single cells using smart-seq2. Nat. Protoc. 2014, 9:171-181.
69. Pilati P., Mocellin S., Bertazza L., et al. Prognostic value of putative circulating cancer stem cells in patients undergoing hepatic resection for colorectal liver metastasis. Ann. Surg. Oncol. 2012, 19:402-408.
70. Pixberg C.F., Schulz W.A., Stoecklein N.H., Neves R.P. Characterization of DNA methylation in circulating tumor cells. Genes (Basel) 2015 Oct 21, 6(4):1053-1075.
71. Plaks V., Koopman C.D., Werb Z. Cancer. circulating tumor cells. Science 2013, 341(6151):1186-1188.
72. Powell A.A., Talasaz A.H., Zhang H., et al. Single cell profiling of circulating tumor cells: transcriptional heterogeneity and diversity from breast cancer cell lines. PLoS One 2012, 7:e33788.
73. Pulukuri S.M., et al. Frequent loss of cystatin E/M expression implicated in the progression of prostate cancer. Oncogene 2009, 28:2829-2838.
74. Punnoose E.A., Atwal S.K., Spoerke J.M., et al. Molecular biomarker analyses using circulating tumor cells. PLoS One 2010, 5:e12517.
75. Reinholz M.M., Kitzmann K.A., Tenner K., et al. Cytokeratin-19 and mammaglobin gene expression in circulating tumor cells from metastatic breast cancer patients enrolled in North Central Cancer Treatment Group trials, N0234/336/436/437. Clin. Cancer Res. 2011, 17:7183-7193.
76. Rivenbark A.G., Jones W.D., Coleman W.B. DNA methylation-dependent silencing of CST6 in human breast cancer cell lines. Lab Invest 2006, 86:1233-1242.
77. Saloustros E., Perraki M., Apostolaki S., et al. Cytokeratin-19 mRNA-positive circulating tumor cells during follow-up of patients with operable breast cancer: prognostic relevance for late relapse. Breast Cancer Res. 2011, 13:R60.
78. Salvianti F., Pazzagli M., Pinzani P. Single circulating tumor cell sequencing as an advanced tool in cancer management. Expert Rev. Mol. Diagn. 2016, 16(1):51-63.
79. Sergeant G., Roskams T., van Pelt J., et al. Perioperative cancer cell dissemination detected with a real-time RT-PCR assay for EpCAM is not associated with worse prognosis in pancreatic ductal adenocarcinoma. BMC Cancer 2011, 11:47.
80. Shimada R., Iinuma H., Akahane T., et al. Prognostic significance of CTCs and CSCs of tumor drainage vein blood in Dukes' stage B and C colorectal cancer patients. Oncol. Rep. 2012, 27:947-953.
81. Shridhar R., et al. Cystatin M suppresses the malignant phenotype of human MDA-MB-435S cells. Oncogene 2004, 23:2206-2215.
82. Sieuwerts A.M., Jeffrey S.S. Multiplex molecular analysis of CTCs. Recent Results Cancer Res. 2012, 195:125-140.
83. Sieuwerts A.M., Kraan J., Bolt-de Vries J., et al. Molecular characterization of circulating tumor cells in large quantities of contaminating leukocytes by a multiplex real-time PCR. Breast Cancer Res. Treat 2009, 118:455-468.
84. Sieuwerts A.M., Mostert B., Bolt-de Vries J., et al. mRNA and microRNA expression profiles in circulating tumor cells and primary tumors of metastatic breast cancer patients. Clin. Cancer Res. 2011, 17:3600-3618.
85. Sotiropoulou G., Anisowicz A., Sager R. Identification, cloning, and characterization of cystatin M, a novel cysteine proteinase inhibitor, down-regulated in breast cancer. J. Biol. Chem. 1997, 272:903-910.
86. Stathopoulou A., Gizi A., Perraki M., et al. Real-time quantification of CK-19 mRNA-positive cells in peripheral blood of breast cancer patients using the lightcycler system. Clin. Cancer Res. 2003, 9:5145-5151.
87. Stathopoulou A., Ntoulia M., Perraki M., et al. A highly specific real-time RT-PCR method for the quantitative determination of CK-19 mRNA positive cells in peripheral blood of patients with operable breast cancer. Int. J. Cancer 2006, 119:1654-1659.
88. Stenman G., Astrom A.K., Roijer E., Sotiropoulou G., Zhang M., Sager R. Assignment of a novel cysteine proteinase inhibitor (CST6) to 11q13 by fluorescence in situ hybridization. Cytogenet. Cell Genet. 1997, 76:45-46.
89. Strati A., Markou A., Parisi C., et al. Gene expression profile of circulating tumor cells in breast cancer by RT-qPCR. BMC Cancer 2011, 11:422.
90. Sugimachi K., Yokobori T., Iinuma H., et al. Aberrant expression of Plastin-3 via Copy number gain induces the epithelial-mesenchymal transition in circulating colorectal Cancer cells. Ann. Surg. Oncol. 2014 Oct 2013, 21(11):3680-3690. Epub 2013 Nov 12. 10.1245/s10434-013-3366-y.
91. Swennenhuis J.F., Terstappen L. Sample preparation methods following CellSearch approach compatible of single-cell whole-genome amplification: an overview. Methods Mol. Biol. 2015, 1347:57-67.
92. Tewes M., Aktas B., Welt A. Molecular profiling and predictive value of circulating tumor cells in patients with metastatic breast cancer: an option for monitoring response to breast cancer related therapies. Breast Cancer Res. Treat 2009, 115:581-590.
93. Ting D.T., Wittner B.S., Ligorio M., Vincent Jordan N., Shah A.M., Miyamoto D.T., Aceto N., Bersani F., Brannigan B.W., Xega K., Ciciliano J.C., Zhu H., MacKenzie O.C., Trautwein J., Arora K.S., Shahid M., Ellis H.L., Qu N., Bardeesy N., Rivera M.N., Deshpande V., Ferrone C.R., Kapur R., Ramaswamy S., Shioda T., Toner M., Maheswaran S., Haber D.A. Single-cell RNA sequencing identifies extracellular matrix gene expression by pancreatic circulating tumor cells. Cell Rep 2014 Sep 25, 8(6):1905-1918.
94. Toss A., Cristofanilli M. Molecular characterization and targeted therapeutic approaches in breast cancer. Breast Cancer Res. 2015 Apr 23, 17:60.
95. Ueo H., Sugimachi K., Gorges T.M., Bartkowiak K., Yokobori T., Müller V., Shinden Y., Ueda M., Ueo H., Mori M., Kuwano H., Maehara Y., Ohno S., Pantel K., Mimori K. Circulating tumour cell-derived plastin3 is a novel marker for predicting long-term prognosis in patients with breast cancer. Br. J. Cancer 2015 Apr 28, 112(9):1519-1526.
96. Vaidya K.S., Harihar S., Phadke P.A., et al. Breast cancer metastasis suppressor-1 differentially modulates growth factor signaling. J. Biol. Chem. 2008, 283:28354-28360.
97. Xenidis N., Perraki M., Kafousi M., et al. Predictive and prognostic value of peripheral blood cytokeratin-19 mRNA-positive cells detected by real-time polymerase chain reaction in node-negative breast cancer patients. J. Clin. Oncol. 2006, 24:3756-3762.
98. Xenidis N., Markos V., Apostolaki S., et al. Clinical relevance of circulating CK-19 mRNA-positive cells detected during the adjuvant tamoxifen treatment in patients with early breast cancer. Ann. Oncol. 2007, 18:1623-1631.
99. Xenidis N., Ignatiadis M., Apostolaki S., et al. Cytokeratin-19 mRNA-positive circulating tumor cells after adjuvant chemotherapy in patients with early breast cancer. J. Clin. Oncol. 2009, 27:2177-2184.
100. Xenidis N., Perraki M., Apostolaki S., et al. Differential effect of adjuvant taxane-based and taxane-free chemotherapy regimens on the CK-19 mRNA-positive circulating tumour cells in patients with early breast cancer. Br. J. Cancer 2013, 108:549-556.
101. Yates D.R., Rouprêt M., Drouin S.J., et al. Quantitative RT-PCR analysis of PSA and prostate-specific membrane antigen mRNA to detect circulating tumor cells improves recurrence-free survival nomogram prediction after radical prostatectomy. Prostate 2012, 72:1382-1388.
102. Yokobori T., Iinuma H., Shimamura T., et al. Plastin3 is a novel marker for circulating tumor cells undergoing the epithelial-mesenchymal transition and is associated with colorectal cancer prognosis. Cancer Res. 2013, 73:2059-2069.
103. Yu M., Ting D.T., Stott S.L., Wittner B.S., Ozsolak F., Paul S., Ciciliano J.C., Smas M.E., Winokur D., Gilman A.J., Ulman M.J., Xega K., Contino G., Alagesan B., Brannigan B.W., Milos P.M., Ryan D.P., Sequist L.V., Bardeesy N., Ramaswamy S., Toner M., Maheswaran S., Haber D.A. RNA sequencing of pancreatic circulating tumour cells implicates WNT signalling in metastasis. Nature 2012 Jul 26, 487(7408):510-513.
104. Zhang L., Riethdorf S., Wu G., et al. Meta-analysis of the prognostic value of circulating tumor cells in breast cancer. Clin. Cancer Res. 2012, 18:5701-5710.
105. Zhao S., Liu Y., Zhang Q., et al. The prognostic role of circulating tumor cells (CTCs) detected by RT-PCR in breast cancer: a meta-analysis of published literature. Breast Cancer Res. Treat 2011, 130:809-816.
106. Zhao S., Yang H., Zhang M., et al. Circulating tumor cells (CTCs) detected by triple-marker EpCAM, CK19, and hMAM RT-PCR and their relation to clinical outcome in metastatic breast cancer patients. Cell Biochem Biophys 2013, 65:263-273.
107. Zheng X., Carstens J.L., Kim J., Scheible M., Kaye J., Sugimoto H., Wu C.C., LeBleu V.S., Kalluri R. Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer. Nature 2015, 527(7579):525-530.